Picture: Andrew Brookes/Getty Photographs
Intermountain Well being spin-off End result Bio has introduced a partnership with BillionToOne in oncology diagnostics.
BillionToOne leverages End result Bio's information lake and affected person recruitment capabilities for diagnostic take a look at validation. The checks contain DNA sequencing applied sciences known as NGS. The diagnostic checks are Northstar Choose, an NGS-based liquid biopsy take a look at that gives data on which therapies could also be applicable for sufferers with stage III/IV most cancers; and Northstar Response, a tissue-free NGS-based therapy response.
Northstar Response quantifies modifications within the quantity of methylated ctDNA in sufferers receiving most cancers therapies to report therapy effectiveness by way of development, response, or secure illness.
WHY THIS MATTERS
BillionToOne is growing these diagnostics to handle the challenges related to precisely profiling most cancers to assist decide the perfect therapy after which monitoring response, a essential think about figuring out the effectiveness of most cancers therapy, the businesses stated.
This collaboration includes two separate tasks, making future regulatory submissions attainable. The primary 100-patient mission, launched in early fall, has already seen progress, with 60 affected person samples collected, many involving uncommon mutations, to this point, End result Bio stated.
THE BIGGEST TREND
In November 2023, Merck World Well being Innovation Fund and Amgen Ventures invested $10 million in End result Bioentures. In January, the corporate introduced a multi-year analysis and growth partnership with Merck to check autoimmune ailments.
End result Bio acts as a “search engine” for scientific information and affected person organic samples. It has information and bodily biosamples from the final 40 years.
The Intermountain Healthcare firm collaborates with enterprise companions, together with expertise and biopharmaceutical corporations, to offer insights, therapeutic targets, diagnostic alternatives and care course of fashions.
IN THE REGISTER
“Our partnership with BillionToOne demonstrates our dedication to advancing healthcare by supporting modern diagnostic options,” stated Mark Oldroyd, Chief Industrial Officer of End result Bio. “By offering entry to our research-focused biospecimen-based information, we’re not solely accelerating novel scientific growth, however we’re additionally paving the way in which for improved diagnostics that promise to rework oncology care.”
“End result Bio's distinctive sources have been instrumental in overcoming the problem of acquiring high-quality samples and information for our validation research,” stated Gary Palmer, CMO of Oncology at BillionToOne.
Electronic mail the author: SMorse@himss.org